Systemic Cidofovir in Papillomatosis

Valckenborgh, Isabelle Van; Wellens, W; Boeck, K. De; Snoeck, Robert; Clercq, Erik De; Feenstra, Louw

doi:10.1086/318497

Cited by 29 publications

(24 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12) (167 (167,168) to conclude that intralesional injection of cidofovir may be of benefit in the treatment of severe respiratory papillomatosis in pediatric patients. From three case studies, it now appears that systemic (intravenous) cidofovir, whether combined with alpha interferon or used alone, would also be effective against recurrent respiratory papillomatosis with involvement of the lung parenchyma (11,58,221); under these conditions, laryngeal and tracheal lesions may regress or even disappear and pulmonary lesions may undergo consolidation.…”

Section: Downloaded Frommentioning

confidence: 99%

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

2003

View full text Add to dashboard Cite

The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections. Cidofovir (Vistide) has been officially approved for the treatment of CMV retinitis in AIDS patients, tenofovir disoproxil fumarate (Viread) has been approved for the treatment of HIV infections (i.e., AIDS), and adefovir dipivoxil (Hepsera) has been approved for the treatment of chronic hepatitis B. Nephrotoxicity is the dose-limiting side effect for cidofovir (Vistide) when used intravenously (5 mg/kg); no toxic side effects have been described for adefovir dipivoxil and tenofovir disoproxil fumarate, at the approved doses (Hepsera at 10 mg orally daily and Viread at 300 mg orally daily)

show abstract

Section: Downloaded Frommentioning

confidence: 99%

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

2003

View full text Add to dashboard Cite

show abstract

“…Armbruster et al reported a successful experience using a combination of intravenous cidofovir and IFN-α-2b in a 34-year-old woman with RRP and bilateral round areas of cavitation and consolidation (8). Van Valckenborgh et al reported the case of an 8-year-old girl who showed significant regression of lung lesions and no side effects after intravenous cidofovir therapy (9). De Bilderling reported one completely cured case of an 8-year-old girl, with suspected lung lesions of respiratory papillomatosis, who remained in remission for at least 2 years (10).…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Spread of Juvenile Laryngeal Papillomatosis: A Case Report

Zhang

2016

Iran J Pediatr

View full text Add to dashboard Cite

Introduction: Recurrent respiratory papillomatosis (RRP) is usually a relatively benign disease but can have an aggressive clinical course. The primary treatment for laryngeal papillomatosis is endoscopic resection. However, there is no effective treatment for pulmonary spread of laryngeal papillomatosis. Case Presentation: We describe a rare case of a 19-year-old man with pulmonary spread of laryngeal papillomatosis. The treatment regimen was surgical resection under general anesthesia using suspension laryngoscopy and endoscopy. The patient had been diagnosed with laryngeal papillomatosis and had undergone a tracheotomy when he was 18 months old. He underwent 17 endoscopic resections for laryngeal papillomatosis at intervals of 3 months to 1 year. At follow-up, the patient continued to have tracheal intubation and was not extubated. CT scans revealed multiple nodular and cavitary lesions in both lungs. Laryngoscopy performed when the patient was 18 years showed diffuse papillomata in the glottis and left ventricular fold. Conclusions: This article presents a rare case of juvenile laryngeal papillomatosis associated with the human papilloma virus (HPV) HPV-11 and pulmonary spread. Intravenous cidofovir has oncogenic potential, but it has been used successfully to treat five patients with pulmonary spread of RRP. Intravenous cidofovir should be considered as salvage therapy.

show abstract

“…Cidofovir and interferon-a-2b in a 34-year-old woman with bilateral round cavitating consolidations due to recurrent respiratory papillomatosis. The only case report involving a child was an 8-year-old Chinese girl [Van Valckenborgh et al, 2001] who showed significant regression of lung lesions and no side effects after 23 doses of i.v. Cidofovir (5 mg/kg).…”

Section: Discussionmentioning

confidence: 99%

“…She was started on weekly injections of 5 mg/kg of i.v. Cidofovir (Vistide 1 ), according to the prescribed protocol [Van Valckenborgh et al, 2001]. Injections were preceded by 24 hr hyperhydration and associated with probenecid (25 mg/kg then 10 mg/kg/6 hr for 24 hr).…”

Section: Case Reportmentioning

confidence: 99%

“…Intralesional injections of Cidofovir have been used with success since 1993 [Van Cutsem et al, 1995]. More recently, some case reports have suggested the usefulness of systemic Cidofovir in the treatment of severe recurrent respiratory papillomatosis in adults [Dancey et al, 2000;Armbruster et al, 2001] and children [Van Valckenborgh et al, 2001].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation